Business Context and Reporting Period
Company: Basel Medical Group Ltd (BMGL)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025 (FY2025)
Business Overview: A British Virgin Islands holding company operating a network of orthopedic, trauma, sports medicine, neurosurgical, and general practice clinics in Singapore. The company recently expanded its footprint through the acquisition of Bethesda Medical Pte Ltd, adding six general practice clinics to its portfolio.
Key Financial Metrics (FY2025 vs. FY2024)
| Metric | FY2025 (US$) | FY2025 (S$) | FY2024 (S$) |
|---|---|---|---|
| Revenue | 8,900,027 | 11,319,944 | 10,050,923 |
| Profit/(Loss) Before Tax | (9,832,138) | (12,505,497) | 2,404,561 |
| Net Loss | (9,503,974) | (12,088,104) | 2,072,800 (Profit) |
| Cash and Cash Equivalents | 2,342,230 | 2,979,083 | 1,951,053 |
| Total Borrowings | 2,688,478 | 3,419,476 | 4,289,790 |
| Goodwill Impairment | (8,763,025) | (11,145,691) | - |
Note: US$ figures are translated from S$ at the rate of S$1 = US$0.7863 (approx) as of June 30, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 12.6% (S$1.27M) primarily driven by the acquisition of the Bethesda Medical group (contributing S$895k) and a rebound in corporate patient volume post-pandemic.
- Profitability Reversal: The company swung from a profit of S$2.4M in FY2024 to a loss of S$12.5M in FY2025. This is almost entirely attributable to a full impairment of goodwill (S$11.1M) recognized on the Bethesda acquisition, as the subsidiary's operations had not yet been turned around.
- Expense Increases: Employee benefit expenses rose 75.8% due to increased headcount and bonuses. Depreciation increased 123.4% due to right-of-use assets from the new clinics. Other operating expenses increased 120.3% due to professional fees and exchange losses.
- Debt Reduction: Total borrowings decreased significantly as the company settled all outstanding term loans during the year, leaving only lease liabilities and a small bank overdraft.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management intends to retain earnings to fund business development and expansion into general practices and other Southeast Asian markets. The company plans to open new orthopedic specialist clinics in Farrer Park, Novena, and Orchard, and has incorporated entities for eye specialist and imaging services.
Unusual Items
- Goodwill Impairment: A non-cash charge of S$11.1M was recorded for the Bethesda acquisition goodwill.
- Related Party Settlement: A significant amount due from a former director and related parties (S$11.9M) was fully settled by the controlling shareholder, Rainforest Capital VCC, during the period.
Risks and Contingencies
- Audit Disclaimer: The independent auditor (NLA DFK Assurance PAC) issued a Disclaimer of Opinion on the financial statements. They could not obtain sufficient evidence regarding the acquisition of Bethesda Medical (fair value of assets/liabilities and goodwill) due to a lack of access to complete accounting records and an ongoing Purchase Price Allocation (PPA) exercise.
- Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting due to a lack of adequately skilled staff with IFRS knowledge.
- Going Concern: The ability to continue as a going concern is dependent on the major shareholder's financial support and the ability to generate sustainable operating profits.
- Key Personnel: The business is heavily dependent on key medical practitioners; loss of these individuals could materially adversely affect operations.
Investor Verification Checklist
- Audit Opinion Status: Verify the implications of the auditor's "Disclaimer of Opinion" regarding the Bethesda acquisition and the reliability of the reported goodwill impairment.
- Goodwill Valuation: Confirm the final Purchase Price Allocation (PPA) results once completed to validate the S$11.1M impairment charge.
- Internal Controls: Assess the progress of hiring skilled IFRS staff and remediation of the identified material weakness in financial reporting.
- Related Party Support: Review the formal commitment from Rainforest Capital VCC regarding the 12-month financial support to ensure liquidity stability.
- Acquisition Integration: Monitor the operational turnaround of the Bethesda Medical clinics to determine if future revenue growth justifies the acquisition cost.